Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)

MLA

Leppa, Sirpa, et al. “Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC Trial).” Blood, vol. 128, no. 22, Dec. 2016, p. 1854. EBSCOhost, https://doi.org/10.1182/blood.V128.22.1854.1854.

APA

Leppa, S., Joergensen, J., Tierens, A., Østlie, I., Fagerli, U. M., Brown, P. de N., Larsen, T. S., Mannisto, S., Munksgaard, L., Maisenhölder, M., Vasala, K., Meyer, P., Jerkeman, M., Bjorkholm, M., Fluge, O., Jyrkkio, S., Ralfkiaer, E., Spetalen, S., Karjalainen-Lindsberg, M.-L., & Holte, H. (2016). Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial). Blood, 128(22), 1854. https://doi.org/10.1182/blood.V128.22.1854.1854

Chicago

Leppa, Sirpa, Judit Joergensen, Anne Tierens, Ingunn Østlie, Unn Merete Fagerli, Peter de Nully Brown, Thomas S Larsen, et al. 2016. “Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC Trial).” Blood 128 (22): 1854. doi:10.1182/blood.V128.22.1854.1854.